Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Beta-Lipotropin (1-10), Porcine Mechanism, Clinical Value, a

    2025-07-02

    Beta-Lipotropin (1-10), Porcine: Mechanism, Clinical Value, and Research Perspectives

    Introduction
    Beta-Lipotropin (1-10), porcine, is a synthetic peptide fragment derived from the N-terminal sequence of the full-length beta-lipotropin (β-LPH) protein, which is itself a cleavage product of pro-opiomelanocortin (POMC). The decapeptide sequence, corresponding to amino acids 1 through 10 of porcine β-LPH, has garnered interest for its diverse biological activities, particularly in the context of neuroendocrine signaling and metabolic regulation (Liotta et al., 1978, Science). The peptide is structurally characterized by the sequence: Ala-Pro-Gly-Lys-Ser-Asp-Glu-Glu-Glu-Glu, which confers unique physicochemical properties and receptor interactions.

    The mechanism of action of Beta-Lipotropin (1-10) is primarily attributed to its role as a neuropeptide modulator. While the full-length β-LPH is known for its lipolytic and melanotropic activities, the N-terminal fragment (1-10) is implicated in neuromodulation, opioid receptor interactions, and possibly in the regulation of pituitary hormone release (Liotta et al., 1978, Science; Kastin et al., 1979, J Biol Chem). The peptide’s ability to cross the blood-brain barrier and interact with central nervous system (CNS) receptors underpins its potential therapeutic applications.

    [Related: VEGF receptor inhibitor and AHR agonist] Clinical Value and Applications
    Beta-Lipotropin (1-10), porcine, has been investigated for its clinical value in several domains, including neuroendocrinology, metabolic disorders, and pain modulation. Its primary clinical significance lies in its potential as a research tool for elucidating the physiological roles of POMC-derived peptides and as a candidate for therapeutic intervention in select CNS disorders.

    1. **Neuroendocrine Regulation:** The peptide’s ability to modulate pituitary hormone secretion has been demonstrated in both in vitro and in vivo models (Kastin et al., 1979, J Biol Chem). This property is of interest for understanding the pathophysiology of disorders such as Cushing’s disease and Addison’s disease, where POMC processing is dysregulated.

    [Related: aminopeptidase B] 2. **Opioid Receptor Modulation:** Beta-Lipotropin (1-10) exhibits weak opioid activity, suggesting a role in modulating pain perception and stress responses (Liotta et al., 1978, Science). This has implications for the development of novel analgesics with reduced side-effect profiles compared to traditional opioids.

    3. **Metabolic Effects:** Although the full-length β-LPH is more potent in stimulating lipolysis, the (1-10) fragment may contribute to metabolic regulation through indirect mechanisms, such as influencing hypothalamic signaling pathways (Bicknell, 2008, J Neuroendocrinol).

    [Related: 740y-p] 4. **Research Tool:** The synthetic peptide is widely used in experimental settings to dissect the functional domains of β-LPH and to study the structure-activity relationships of POMC-derived peptides (Smith et al., 2007, Peptides).

    Key Challenges and Pain Points Addressed
    Current treatments for neuroendocrine and metabolic disorders often lack specificity, leading to significant off-target effects and limited efficacy. Beta-Lipotropin (1-10), porcine, addresses several key challenges:

    - **Targeted Modulation:** By focusing on a specific functional domain of β-LPH, researchers can achieve more targeted modulation of neuroendocrine pathways, potentially reducing unwanted systemic effects.

    - **Blood-Brain Barrier Penetration:** The small size and physicochemical properties of the (1-10) fragment enhance its ability to cross the blood-brain barrier, a major limitation for many peptide-based therapeutics (Banks & Kastin, 1985, Peptides).

    - **Reduced Opioid Side Effects:** The weak opioid activity of Beta-Lipotropin (1-10) may allow for pain modulation with a lower risk of addiction and respiratory depression compared to classical opioids (Liotta et al., 1978, Science).

    - **Research Versatility:** The peptide’s defined sequence and synthetic accessibility make it an ideal tool for structure-function studies, facilitating the development of next-generation neuropeptide therapeutics.

    Literature Review
    A growing body of literature supports the biological relevance and research utility of Beta-Lipotropin (1-10), porcine. Key studies include:

    1. **Liotta et al. (1978, Science):** This seminal study characterized the opioid activity of β-LPH fragments, including the (1-10) sequence, and demonstrated their ability to bind to opioid receptors in the CNS.

    2. **Kastin et al. (1979, J Biol Chem):** The authors investigated the neuroendocrine effects of β-LPH fragments, showing that the (1-10) peptide can modulate pituitary hormone release in animal models.

    3. **Banks & Kastin (1985, Peptides):** This study explored the transport of β-LPH fragments across the blood-brain barrier, highlighting the enhanced CNS penetration of the (1-10) peptide.

    4. **Bicknell (2008, J Neuroendocrinol):** A comprehensive review of POMC-derived peptides, including β-LPH and its fragments, discussing their roles in neuroendocrine regulation and metabolic control.

    5. **Smith et al. (2007, Peptides):** The authors utilized synthetic β-LPH fragments to delineate the structure-activity relationships governing receptor interactions and biological activity.

    6. **Yamada et al. (1982, Endocrinology):** This study examined the effects of β-LPH fragments on ACTH secretion, providing evidence for the regulatory role of the (1-10) sequence.

    7. **Guillemin et al. (1977, Proc Natl Acad Sci USA):** Early work on POMC processing and the identification of biologically active fragments, including β-LPH (1-10), in the pituitary.

    Collectively, these studies establish Beta-Lipotropin (1-10), porcine, as a biologically active peptide with significant research and potential clinical applications.

    Experimental Data and Results
    Experimental investigations into Beta-Lipotropin (1-10), porcine, have focused on its receptor binding properties, neuroendocrine effects, and pharmacokinetics.

    - **Receptor Binding:** Liotta et al. (1978) demonstrated that the (1-10) fragment binds to opioid receptors with lower affinity than full-length β-LPH or endorphins, but retains measurable activity in radioligand binding assays.

    - **Hormone Secretion:** Kastin et al. (1979) reported that administration of the (1-10) peptide in rats led to modest but significant changes in pituitary hormone levels, including ACTH and β-endorphin, suggesting a role in feedback regulation.

    - **Blood-Brain Barrier Transport:** Banks & Kastin (1985) showed that radiolabeled β-LPH (1-10) crosses the blood-brain barrier more efficiently than larger peptide fragments, supporting its utility in CNS research.

    - **Metabolic Effects:** While direct lipolytic activity is limited, Bicknell (2008) noted that the (1-10) fragment may influence hypothalamic pathways involved in energy balance and appetite regulation.

    - **Structure-Activity Relationships:** Smith et al. (2007) used alanine-scanning mutagenesis to identify key residues in the (1-10) sequence responsible for receptor binding and biological activity, providing a foundation for rational peptide design.

    These findings underscore the multifaceted biological activity of Beta-Lipotropin (1-10), porcine, and its value as a research tool.

    Usage Guidelines and Best Practices
    For research applications, Beta-Lipotropin (1-10), porcine, should be handled and administered according to established peptide research protocols. Key guidelines include:

    - **Storage:** The peptide should be stored at -20°C or lower, protected from moisture and light. Lyophilized powder is stable for extended periods under these conditions.

    - **Reconstitution:** Reconstitute the peptide in sterile distilled water or appropriate buffer (e.g., PBS) to the desired concentration. Avoid repeated freeze-thaw cycles to maintain peptide integrity.

    - **Dosage:** Experimental dosages vary depending on the model system and research objective. Typical in vivo studies utilize doses ranging from 0.1 to 10 mg/kg, administered via intraperitoneal or intracerebroventricular injection (Kastin et al., 1979). In vitro studies often use concentrations in the micromolar range.

    - **Controls:** Include appropriate negative and positive controls to account Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 33 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11567666